In the STEP-1 trial (N=1,961), 44.2% of participants receiving semaglutide 2.4 mg reported nausea compared to 17.4% on placebo [1]
Theyre also high in saturated fat, which is linked to heart disease
This milestone represents a meaningful shift in Novo Nordisk recently received FDA approval to bring its oral semaglutide formulation, Rybelsus, under the Ozempic brand aligning oral and injectable semaglutide for type 2 diabetes under a single, highly recognized name On February 24, 2026, Novo Nordisk announced it will significantly reduce the wholesale acquisition cost (WAC) of several of its GLP1 therapies, effective January 1, 2027
Avoid overeating, skipping meals, or drinking too much alcohol
Zepbound also targets GIP, a hormone that helps to regulate blood sugar levels and metabolism
Key features of semaglutide include Appetite suppression: Semaglutide helps to reduce feelings of hunger and increase feelings of fullness, making it easier to stick to a calorie-restricted diet